Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.82 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.59 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.59 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.59 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3934396 | 0.90 | BRAF (1.00) | BRAFCYP2C9LCKKDRBTK | |
| SCHEMBL3937282 | 0.90 | BRAF (0.85) | BRAFCYP2C9LCKKDRBTK | |
| SCHEMBL3941588 | 0.89 | BRAF (0.82) | BRAFCYP2C9LCKKDRBTK | |
| SCHEMBL3932791 | 0.89 | BRAF (1.00) | BRAFCYP2C9LCKKDRBTK | |
| SCHEMBL3932579 | 0.89 | BRAF (1.00) | BRAFCYP2C9LCKKDRBTK | |
| SCHEMBL3929867 | 0.88 | BRAF (1.00) | BRAFCYP2C9LCKKDRBTK | |
| SCHEMBL3934670 | 0.88 | BRAF (0.88) | BRAFCYP2C9LCKKDRBTK | |
| SCHEMBL3942817 | 0.87 | BRAF (1.00) | BRAFCYP2C9LCKKDRBTK | |
| SCHEMBL3929892 | 0.87 | BRAF (1.00) | BRAFCYP2C9LCKKDRBTK | |
| SCHEMBL3936063 | 0.87 | BRAF (1.00) | BRAFCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |